Abstracts tagged "Cohort Study"

Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Joyce (Yun-Ting) Huang¹, David Jenkins², Belay Birlie Yimer¹, Jose Benitez-Aurioles², Niels Peek², Mark Lunt¹, Will Dixon³ and Meghna Jani¹, ¹Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Division of Informatics, The University of Manchester, Manchester, United Kingdom, ³The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…
Abstract Number: 1667 • ACR Convergence 2022
Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibitors for Cancer Treatment: A Comparative Cohort Study Investigating RA Flare and Mortality
Kaitlin McCarter¹, Taylor Wolfgang¹, Senada Arabelovic¹, Xiaosong Wang¹, Kazuki Yoshida¹, Emily Banasiak¹, Grace Qian¹, Emily Kowalski¹, Kathleen Vanni¹, Nicole LeBoeuf¹, Elizabeth Buchbinder¹, Lydia Gedmintas¹, Lindsey MacFarlane¹, Deepak Rao¹, Nancy Shadick¹, Ellen Gravallese² and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: For patients with pre-existing RA, immune checkpoint inhibitors (ICIs) for cancer treatment may trigger RA flares or other immune-related adverse events. Underlying altered immunity…
Abstract Number: 2018 • ACR Convergence 2022
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Alja Stel³, Greetje van Zuiden³, Jolien van Nimwegen², Arjan Vissink⁴, Frans Kroese², Gwenny Verstappen² and Hendrika Bootsma², ¹UMCG, Zwolle, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
Abstract Number: 0281 • ACR Convergence 2022
Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions
Maya Buch¹, BERNARD COMBE², Jose A Gomez-Puerta³, Roberto Felice Caporali⁴, jacques-eric gottenberg⁵, Paul Van Hoek⁶, Vijay Rajendran⁷, Pieter-Jan Stiers⁶, Katrien Van Beneden⁶, Daniel Aletaha⁸, Gerd Burmester⁹, Rene Westhovens¹⁰ and Yoshiya Tanaka¹¹, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Montpellier University, Montpellier, France, ³Hospital Clínic de Barcelona, Barcelona, Spain, ⁴University of Milan, Milano, Italy, ⁵Strasbourg University Hospital, Strasbourg, France, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos NV, Gent, Belgium, ⁸Medical University Vienna, Wien, Austria, ⁹Charité University Medicine Berlin, Berlin, Germany, ¹⁰University Hospitals Leuven, Leuven, Belgium, ¹¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor approved for the treatment of moderate to severe active RA.1 It was previously reported that…
Abstract Number: 0819 • ACR Convergence 2022
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
Anchal Sabharwal¹, Yuanqing Liu¹, Yazmin Rustomji¹ and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Connective tissue diseases (CTDs) are a category of autoimmune disease in which interstitial lung disease (ILD) is a common pulmonary manifestation. Due to the…
Abstract Number: 1244 • ACR Convergence 2022
Incidence of Radiographic Spinal Damage in Psoriatic Arthritis Patients Compared to Spondyloarthritis Patients: Which Patients Are More Affected?
Manouk de Hooge¹, Alla Alexeevna Ishchenko², Ann-Sophie Kathleen De Craemer³, Serge Steinfeld⁴, Adrien NZEUSSEU TOUKAP⁵, Filip Van den bosch⁶, Dirk Elewaut⁷, Rik Lories⁸ and Kurt de Vlam⁹, ¹Ghent University Hospital, Luxembourg, Luxembourg, ²University Hospitals Leuven, Sint-Stevens-Woluwe, Belgium, ³Ghent University Hospital, Gent, Belgium, ⁴Clinique Saint-Jean, Brussels, Belgium, ⁵Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁶Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁷Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁸KU Leuven, Leuven, Belgium, ⁹University Hospitals Leuven, Leuven, Belgium
Background/Purpose: There is an ongoing debate on axial involvement in psoriatic arthritis (PsA) patients. This study reports the baseline radiographic spinal damage in PsA and…
Abstract Number: 1761 • ACR Convergence 2022
Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies suggest that seropositive and seronegative rheumatoid arthritis (RA) patients may respond differently to disease-modifying anti-rheumatic drugs (DMARDs). However, little is known about…
Abstract Number: 2025 • ACR Convergence 2022
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
Brandon Law¹, Margaret Beach², Eileen Pelayo², Ilias Alevizos², Zohreh Khavandgar², Blake Warner² and Alan Baer¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: The objectives of this study were to assess the natural history of Sjögren's disease (SjD) over an interval reaching up to 32 years among…
Abstract Number: 0301 • ACR Convergence 2022
Effectiveness and Safety of Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Third Interim Analysis of a German Non-Interventional, Prospective, Multicenter Study (ESCALATE-RA)
Klaus Krüger¹, Ulrich Prothmann², Thilo Klopsch³, Olaf Behmer⁴, Min-Jean Hsieh⁴, Jürgen Jobst⁴, Pascal Klaus⁴ and Thomas Meng⁴, ¹Praxiszentrum St. Bonifatius, Rheumatology, München, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Germany, ³Rheumatological Practice, Neubrandenburg, Germany, ⁴Pfizer Pharma GmbH, Berlin, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. ESCALATE-RA is the first prospective, non-interventional study with tofacitinib in Germany.Methods:…
Abstract Number: 0934 • ACR Convergence 2022
Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jun Won Park¹, Min Jung Kim², Hyoun-Ah Kim³, Jinhyun Kim⁴, Eun Bong Lee¹ and Kichul Shin⁵, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ³Ajou University School of Medicine, Suwon, Republic of Korea, ⁴Chungnam National University Hospital, Jung-gu, Daejeon, South Korea, ⁵Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: The American College of Rheumatology and the European League Against Rheumatism recommend using methotrexate (MTX) with targeted therapy. Previous studies have shown that tapering…
Abstract Number: 1320 • ACR Convergence 2022
Performance of FRAX® Brazil and NOGG Methodology with and Without Bone Mineral Density upon Predicting Fractures on a Community-Dwelling Elderly Population with High Incidence of Osteoporotic Fractures: The São Paulo Ageing and Health (SPAH) Study
Thiago Q Freitas¹, Leonardo F G Olalla¹, Liliam Takayama¹, Valeria Caparbo², camille figueiredo², Luana Machado³, Diogo Domiciano⁴ and Rosa Pereira², ¹University of São Paulo, São Paulo, Brazil, ²Bone Metabolism Laboratory, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: SPAH is a prospective cohort of ≥65-year-old community-dwelling elderly with high fracture risk (40.3/1,000 person-years in women and 30.6/1,000 in men for vertebral fractures…
Abstract Number: 1780 • ACR Convergence 2022
Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases
Paola Ghanem¹, Joseph C. Murray¹, Christopher Mecoli², Ami Shah³, Benjamin Levy¹, Kristen A. Marrone¹, David Ettinger¹, Valsamo Anagnostou¹, Vincent K. Lam¹, Julie R. Brahmer¹ and Laura C. Cappelli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Lung cancer remains the leading cause of cancer-related death. Concomitant autoimmune diseases (AD) can add morbidity and complicate treatment decisions. We evaluated the tumor…
Abstract Number: 2049 • ACR Convergence 2022
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Phoung Phoung Diep¹, Karoline Lerang², Birgir Gudbransson¹, Helena Andersson¹, Øyvind Midtvedt¹, Torhild Garen¹, Michael Durheim¹, Trond Mogens Aaløkken¹, Øyvind Palm¹ and Øyvind Molberg², ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Jeffrey X. Yang¹, Mehmet Hocaoglu², Jose A Meade-Aguilar¹, Alain Sanchez-Rodriguez¹, Mark Denis P Davis³, Hannah Langenfeld⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…
Abstract Number: 1014 • ACR Convergence 2022
Is Radiographic Axial Involvement Associated with Syndesmophyte Development After 2 Years in PsA Patients?
Manouk de Hooge¹, Alla Alexeevna Ishchenko², Serge Steinfeld³, Adrien NZEUSSEU TOUKAP⁴, Dirk Elewaut⁵, Rik Lories⁶, Filip Van den bosch⁷ and Kurt de Vlam⁸, ¹Ghent University Hospital, Luxembourg, Luxembourg, ²University Hospitals Leuven, Sint-Stevens-Woluwe, Belgium, ³Clinique Saint-Jean, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁵Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁶KU Leuven, Leuven, Belgium, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁸University Hospitals Leuven, Leuven, Belgium
Background/Purpose: There is an ongoing debate on axial involvement in psoriatic arthritis (PsA). This study, using clinical and radiographical definitions of axial involvement, investigated the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].